Table 1. Immunoconjugates and targeted... | American Society of Hematology

Table 1.

Immunoconjugates and targeted therapies for HCL

rIT indicates recombinant immunotoxin; TKI, thymidine kinase inhibitor; and NHL, non-Hodgkin lymphoma.